Title:
Tumor hypoxia and role of hypoxia-inducible factor in oral cancer

dc.contributor.authorPooja Singh
dc.contributor.authorMonika Rajput
dc.contributor.authorManoj Pandey
dc.date.accessioned2026-02-09T04:26:00Z
dc.date.issued2024
dc.description.abstractBackground: Head and neck cancer (HNC) is one of the most frequent malignancies in Asian males with a poor prognosis. Apart from well-known prognostic indicators, markers of tumor hypoxia can help us predict response to treatment and survival. Methods: A review of the literature on the present evidence and potential clinical importance of tumor hypoxia in head and neck cancer was carried out. The data obtained from the literature search is presented as a narrative review. Results: The literature shows possible associations between prognosis and low tumor oxygenation. Intermediate hypoxia biomarkers like HIF-1, GLUT-1, miRNA, and lactate, can help in predicting the response to therapy and survival as their altered expression is related to prognosis. Conclusions: Hypoxia is common in HNC and can be detected by use of biomarkers. The tumors that show expression of hypoxia biomarkers have poor prognosis except for patients with human papilloma virus-associated or VHL-associated cancers. Therapeutic targeting of hypoxia is emerging; however, it is still in its nascent stage, with increasing clinical trials hypoxia is set to emerge as an attractive therapeutic target in HNC. © 2024, The Author(s).
dc.identifier.doi10.1186/s12957-023-03284-3
dc.identifier.issn14777819
dc.identifier.urihttps://doi.org/10.1186/s12957-023-03284-3
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/46959
dc.publisherBioMed Central Ltd
dc.subjectAxitinib
dc.subjectBevacizumab
dc.subjectGlucose metabolism
dc.subjectHypoxia
dc.subjectOral cancer
dc.subjectPazopanib
dc.subjectSunitinib
dc.subjectTP53
dc.subjectVEGF
dc.titleTumor hypoxia and role of hypoxia-inducible factor in oral cancer
dc.typePublication
dspace.entity.typeReview

Files

Collections